SCHEMBL13245144

SCHEMBL13245144

C[C@H](NC(C)(C)C)c1ccc(F)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.39
MC4R P32245 1/20 0.38
SLC6A3 Q01959 2/20 0.38
SLC6A2 P23975 2/20 0.38
CHRNA1 P02708 1/20 0.38
CHRNG P07510 1/20 0.38
CHRNB1 P11230 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
CHRND Q07001 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
NR1I2 O75469 1/20 0.36
SCN1A P35498 1/20 0.36
SCN1B Q07699 1/20 0.36
SCN5A Q14524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14930814 1.00 HDAC6 (0.39) HDAC6MC4RSLC6A3SLC6A2CHRNA1
SCHEMBL10315777 0.84 SLC6A2 (0.37) SLC6A3SLC6A2CHRNA1CHRNGCHRNB1
SCHEMBL14301373 0.83 MC4R (0.41) HDAC6MC4RSLC6A2CES2CES1
SCHEMBL10087182 0.82 APLNR (0.43) SLC6A3SLC6A2CHRNA1CHRNGCHRNB1
SCHEMBL178508 0.79 HTR2A (0.47) HDAC6MC4RSLC6A2CES2CES1
SCHEMBL18475407 0.79 HDAC6 (0.45) HDAC6MC4RSLC6A2CES2CES1
SCHEMBL8298232 0.79 HTR2A (0.47) HDAC6MC4RSLC6A2CES2CES1
SCHEMBL10315773 0.77 HDAC6 (0.41) HDAC6MC4RSLC6A2CES2CES1
SCHEMBL17041219 0.75 HDAC6 (0.38) HDAC6MC4RSLC6A2CES2CES1
SCHEMBL17041226 0.75 HDAC6 (0.38) HDAC6MC4RSLC6A2CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140010784-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-09 US disclosed
US-8486989-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-16 US disclosed
US-20100173851-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2010-07-08 US disclosed
US-20080045480-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED 2008-02-21 US disclosed
US-20070292933-A1 Inhibitors of serine proteases, particular HCV NS3-NS4A protease PITLIK JANOS 2007-12-20 US disclosed
US-7241796-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INC. (US) 2007-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070292933-A1 Inhibitors of serine proteases, particular HCV NS3-NS4A protease SERPINB1, PRSS1, SPINT2 HDAC6 1073/4885MC4R 4431/4885SLC6A3 2647/4885
US-20100173851-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE SERPINB1, PRSS1, SPINT2 HDAC6 1060/4885MC4R 4403/4885SLC6A3 2679/4885
US-20140010784-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE SERPINB1, PRSS1, SPINT2 HDAC6 1468/4885MC4R 3942/4885SLC6A3 3337/4885
US-20080045480-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease SERPINB1, PRSS1, SPINT2 HDAC6 1468/4885MC4R 3942/4885SLC6A3 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.